

Michael Fx Gnant

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7660992/michael-fx-gnant-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

521 papers	37,830 citations	78 h-index	188 g-index
639 ext. papers	43,978 ext. citations	5.8 avg, IF	6.93 L-index

#	Paper	IF	Citations
521	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).. <i>Journal of Clinical Oncology</i> , 2022, JCO2101918	2.2	2
520	Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic.. <i>Lancet Oncology, The</i> , 2022, 23, 195-197	21.7	0
519	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.. <i>Lancet Oncology, The</i> , 2022,	21.7	7
518	Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36	10.1	
517	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022, 82, GS1-07-GS1-07	10.1	
516	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-04-PD2-04	10.1	
515	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. <i>Cancer Research</i> , 2022, 82, P1-02-07-P1-02-07	10.1	
514	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). <i>Cancer Research</i> , 2022, 82, P4-10-01-P4-10-01	10.1	0
513	Abstract DEB1-1: Pro - RxPONDER: Was it all OFS?. <i>Cancer Research</i> , 2022, 82, DEB1-1-DEB1-1	10.1	
512	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022, 82, P4-06-08-P4-06-08	10.1	
511	Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. <i>Cancer Research</i> , 2022, 82, P4-12-01-P4-12-01	10.1	
510	Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.. <i>ESMO Open</i> , 2022, 7, 100426	6	0
509	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.. <i>Breast</i> , 2022, 63, 123-139	3.6	3
508	The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. <i>International Journal of Surgery</i> , 2022, 106694	7.5	0
507	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2021, JCO2102554	2.2	11
506	Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. <i>JCO Global Oncology</i> , 2021, 7, 1513-1521	3.7	0
505	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802	8.7	0

504	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 518-518	2.2	1
503	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1518-1530	2.2	35
502	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 395-405	59.2	8
501	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021 , 21, 80-91.e7	3	52
500	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology, The</i> , 2021 , 22, e18-e28	21.7	13
499	St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. <i>Breast Care</i> , 2021 , 16, 135-143	2.4	29
498	A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort. <i>ESMO Open</i> , 2021 , 6, 100006	6	3
497	PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. <i>British Journal of Surgery</i> , 2021 , 108, 308-314	5.3	6
496	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 212-222	21.7	64
495	ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. <i>ESMO Open</i> , 2021 , 6, 100228	6	4
494	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021 , 27, 5931-5938	12.9	1
493	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology, The</i> , 2021 , 22, 1139-1150	21.7	24
492	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
491	Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posyive Trial. <i>BMC Cancer</i> , 2020 , 20, 392	4.8	8
490	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 545-555	5.1	2
489	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020 , 134, 99-106	7.5	17
488	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020 , 26, 5682-5688	12.9	3
487	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4682-4687	12.9	13

486	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020 , 50, 64-70	3.6	7
485	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. <i>European Journal of Cancer</i> , 2020 , 127, 12-20	7.5	12
484	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 87-96	4.4	3
483	LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16046-e16046	2.2	2
482	Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 588-588	2.2	
481	IDO1 Paneth cells promote immune escape of colorectal cancer. <i>Communications Biology</i> , 2020 , 3, 252	6.7	13
480	The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2017-2024	3.1	5
479	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020 , 126, 1175-1182	6.4	7
478	Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420938458	3	2
477	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology, The</i> , 2020 , 21, e375-e385	21.7	17
476	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020 , 5,	6	74
475	Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 610-618	3.3	56
474	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncologica</i> , 2020 , 59, 75-81	3.2	6
473	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020 , 132, 43-52	7.5	13
472	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 66	51.1	698
471	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. <i>Annals of Oncology</i> , 2019 , 30, 567-574	10.3	11
470	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019 , 25, 2975-2987	12.9	51
469	Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. <i>Breast</i> , 2019 , 46, 101-107	3.6	1

468	The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. <i>Hepatobiliary Surgery and Nutrition</i> , 2019 , 8, 111-124	2.1	7
467	Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2019 , 14, e0215915	3.7	25
466	Prediction of Distant Recurrence Using EndoPredict Among Women with ER, HER2 Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019 , 25, 3865-3872	12.9	36
465	Denosumab in early-stage breast cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2019 , 20, 236	21.7	2
464	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 377-386	4.4	39
463	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019 , 21, 39	8.3	11
462	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019 , 14, 103-110	2.4	84
461	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
460	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1226-1238	21.7	55
459	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019 , 30, 1541-1557	10.3	288
458	Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 1807-1815	4.0	141
457	The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. <i>Cells</i> , 2019 , 8,	7.9	2
456	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1050-1050	2.2	1
455	Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 553-553	2.2	2
454	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 339-351	21.7	106
453	ERR β promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019 , 38, 950-964	9.2	19
452	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019 , 25, 2737-2744	12.9	22
451	Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. <i>Annals of Oncology</i> , 2019 , 30, 109-114	10.3	10

450	Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. <i>Annals of Surgery</i> , 2019 , 269, 1163-1169	7.8	59
449	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncolmunology</i> , 2018 , 7, e1435226	7.2	23
448	Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. <i>British Journal of Surgery</i> , 2018 , 105, 811-819	5.3	21
447	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 316-324	4	37
446	Explained variation in shared frailty models. <i>Statistics in Medicine</i> , 2018 , 37, 1482-1490	2.3	2
445	Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. <i>Annals of Oncology</i> , 2018 , 29, 281-282	10.3	2
444	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018 , 24, 3079-3086	12.9	9
443	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 18	5.4	8
442	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. <i>Gastroenterology</i> , 2018 , 154, 1543-1545	13.3	19
441	TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact. <i>Annals of the New York Academy of Sciences</i> , 2018 , 1434, 46-53	6.5	1
440	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 500-500	2.2	18
439	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 538-538	2.2	1
438	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 524-524	2.2	1
437	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2018 , 26, 1345-1352	3.9	5
436	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39 ^{1.7}	4 ¹³	
435	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 127-138	21.7	62
434	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 78-86	7.1	20
433	Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone - A retrospective cohort study. <i>PLoS ONE</i> , 2018 , 13, e0206911	3.7	7

432	The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 1210	4.8	20
431	Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. <i>Trials</i> , 2018 , 19, 667	2.8	41
430	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. <i>Annals of Surgery</i> , 2018 , 268, 894-902	7.8	43
429	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 523-537	4.4	46
428	IPancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018 , 50, 160-166	0.9	3
427	Toward a Consensus on Centralization in Surgery. <i>Annals of Surgery</i> , 2018 , 268, 712-724	7.8	97
426	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 3676-3683	12.9	14
425	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1011-1018	2.2	63
424	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017 , 7, 1-12	4.5	127
423	Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 421-427	4.4	14
422	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. <i>Breast Care</i> , 2017 , 12, 102-107	2.4	87
421	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
420	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712	10.3	586
419	Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 116-122	7.1	0
418	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
417	Breast cancer. <i>Lancet, The</i> , 2017 , 389, 1134-1150	40	923
416	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 679-692	5.4	10
415	Sized Influences Nodal Status in Women Aged ≥70 with Endocrine Responsive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 555-556	3.1	4

414	Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT 2017 ,		5
413	SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 557-557	2.2	7
412	Primary operation in synchronous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIME trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 557-557	2.2	2
411	ASAMET: A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1591-TPS1591	2.2	2
410	Inflammatory response and oxidative stress during liver resection. <i>PLoS ONE</i> , 2017 , 12, e0185685	3.7	13
409	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. <i>Anticancer Research</i> , 2017 , 37, 2683-2691	2.3	9
408	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). <i>Annals of Oncology</i> , 2017 , 28, v605	10.3	92
407	Adjuvant Treatment with Bone-Targeting Agents (Bisphosphonates and Anti-RANK-Ligand Antibody) 2017 , 593-598		
406	Primary surgery versus no surgery in synchronous metastatic breast cancer: Patient-reported outcomes of the ABCSG 28 Posytime trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1074-1074	2.2	
405	Independent validation of stromal uPA in archived tumor samples from the prospectively randomized ABCSG8 trial to provide level 1b evidence for a prognostic value of uPA immunohistochemistry in endocrine-treated postmenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 536-536	2.2	
404	High accumulation of metformin in colonic tissue of subjects with diabetes or metabolic syndrome.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1557-1557	2.2	
403	Adjuvant Bisphosphonates and Breast Cancer Survival. <i>Annual Review of Medicine</i> , 2016 , 67, 1-10	17.4	20
402	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1310-1315	13.4	285
401	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1888-1896	27.4	58
400	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. <i>Clinical Journal of Oncology Nursing</i> , 2016 , 20, 175-80	1.1	9
399	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016 , 9, 70-75	0.3	
398	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 367-377	21.7	339
397	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016 , 27, 379-90	10.3	135

396	Palbociclib for the treatment of postmenopausal breast cancer - an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 255-63	4	13
395	Abstract OT1-03-21: PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer 2016 ,		3
394	Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial 2016 ,		3
393	Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial 2016 ,		18
392	Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapyBased regimens 2016 ,		6
391	PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1002-1002	2.2	2
390	The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxelHealth-related quality of life during ongoing therapy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1035-1035	2.2	2
389	LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS613-TPS613	2.2	3
388	Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTO trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 604-604	2.2	
387	Prognostic impact of breast cancer subtypes in elderly patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 91-9	4.4	16
386	Editorial comment on 'Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials'. <i>European Journal of Cancer</i> , 2016 , 59, 125-127	7.5	1
385	Pathological complete remission and long-term outcome-what do we know in 2016?. <i>Lancet Oncology</i> , 2016 , 17, 693-694	21.7	2
384	Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2016 , 5, 2350-8	4.8	24
383	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015 , 15, 505-11	3	4
382	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015 , 26, 1685-91	10.3	78
381	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1481-9	7.5	26
380	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015 , 10, 124-30	2.4	61
379	PG 4.03 Targeting bone microenvironment: clinical implications. <i>Breast</i> , 2015 , 24, S8-S9	3.6	

378	Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. <i>Pharmacoeconomics</i> , 2015 , 33, 179-90	4.4	18
377	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
376	Reply to the letter to the editor 'duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients' by Fouad et al. <i>Annals of Oncology</i> , 2015 , 26, 1799-800	10.3	
375	Bevacizumab: no comeback in early breast cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 1001-1003	21.7	3
374	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015 , 8, 54	3.7	242
373	Morbidity reduction using the vessel sealing device LigaSure [®] in breast cancer surgery. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2015 , 47, 150-156	0.9	1
372	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 729-37	4.7	85
371	TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients. <i>EBioMedicine</i> , 2015 , 2, 825-30	8.8	30
370	Targeting bone microenvironment: Clinical implications. <i>Breast</i> , 2015 , 24 Suppl 2, S49-50	3.6	1
369	Denosumab and fracture risk in women with breast cancer - Author's reply. <i>Lancet, The</i> , 2015 , 386, 2057-2058	4.058	5
368	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015 , 26, 313-20	10.3	205
367	Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. <i>Journal of Clinical Oncology</i> , 2015 , 33, 816-22	2.2	152
366	Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases 2015 , 685-689		
365	Breast Cancer Is Our Global Responsibility. <i>Breast Care</i> , 2015 , 10, 360	2.4	5
364	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015 , 112, 1405-10	8.7	56
363	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 386, 433-43	4.0	357
362	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015 , 11, 205-17	3.6	14
361	CDK4/6 inhibitors in luminal breast cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 2-3	21.7	5

360	Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study 2015 ,		3
359	Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study 2015 ,		11
358	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 504-504	2.2	6
357	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 508-508	2.2	12
356	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 551-551	2.2	1
355	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 117-117	2.2	1
354	Prognostic impact of breast cancer (BC) subtype in elderly patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20536-e20536	2.2	
353	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , 2014 , 383, 2127-35	4.0	1237
352	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 771-8	3.5	20
351	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014 , 6, 59-70	0.8	5
350	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. <i>Annals of Oncology</i> , 2014 , 25, 339-45	10.3	239
349	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 <i>Annals of Oncology</i> , 2014 , 25, 2357-2362	10.3	361
348	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014 , 23, 637-43	3.6	41
347	Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification. <i>International Journal of Surgery</i> , 2014 , 12, 334-9	7.5	29
346	Modern therapeutic concepts of early breast cancer. <i>Breast Care</i> , 2014 , 9, 85-6	2.4	1
345	Interview: Aspects of modern breast cancer management: a surgeon's tale. <i>Breast Cancer Management</i> , 2014 , 3, 139-143	0.7	
344	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014 , 27, 906-15	9.8	18
343	The AURORA initiative for metastatic breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1881-7	8.7	68

342	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014 , 9, 344-8	2.4	7
341	The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2-early breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 837-42	8.7	36
340	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. <i>Annals of Oncology</i> , 2014 , 25, 808-815	10.3	103
339	The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1298-305	12.9	144
338	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). <i>Annals of Oncology</i> , 2014 , 25, 366-71	10.3	51
337	1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. <i>European Journal of Cancer</i> , 2014 , 50, S1	7.5	13
336	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. <i>Breast</i> , 2014 , 23, 393-9	3.6	34
335	Role of bisphosphonates in postmenopausal women with breast cancer. <i>Cancer Treatment Reviews</i> , 2014 , 40, 476-84	14.4	24
334	HER2-positive breast cancer: a new piece of the puzzle. <i>Lancet Oncology</i> , 2014 , 15, 668-9	21.7	2
333	Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. <i>World Journal of Surgery</i> , 2014 , 38, 456-62	3.3	9
332	Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. <i>World Journal of Surgery</i> , 2014 , 38, 465-75	3.3	36
331	Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying, enhanced postprandial release of GLP-1, and improved insulin sensitivity. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 52-9	3.3	10
330	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1008-1008	2.2	5
329	Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1130-1130	2.2	1
328	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 529-529	2.2	4
327	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 577-577	2.2	4
326	T-DM1 in HER2-positive breast cancer brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 650-650	2.2	1
325	A cross-section study evaluating patients' satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17574-e17574	2.2	1

324	Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2 \square PIK3CA mutant or wild-type, breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS655-TPS655	2.2	1
323	A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. <i>Anticancer Research</i> , 2014 , 34, 2377-84	2.3	15
322	Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. <i>Anticancer Research</i> , 2014 , 34, 6767-73	2.3	22
321	Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013 , 45, 169-178	0.9	1
320	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 101-11	7	36
319	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 277-85	4.6	47
318	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
317	Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. <i>British Journal of Cancer</i> , 2013 , 109, 1522-7	8.7	28
316	Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013 , 13, 421-432.e8	3	89
315	Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 654-63	9.7	77
314	Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. <i>Advances in Therapy</i> , 2013 , 30, 870-84	4.1	355
313	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013 , 119, 1908-15	6.4	70
312	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013 , 49, 2621-32	7.5	48
311	The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. <i>Current Oncology Reports</i> , 2013 , 15, 14-23	6.3	19
310	Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>British Journal of Cancer</i> , 2013 , 108, 2259-63	8.7	43
309	The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. <i>British Journal of Cancer</i> , 2013 , 109, 589-96	8.7	43
308	Efficacy of tamoxifen \square aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. <i>British Journal of Cancer</i> , 2013 , 108, 1408-14	8.7	21
307	4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013 , 45, 277-281	0.9	

306	St. Gallen 2013: brief preliminary summary of the consensus discussion. <i>Breast Care</i> , 2013 , 8, 102-9	2.4	84
305	Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. <i>Breast Care</i> , 2013 , 8, 293-9	2.4	13
304	CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. <i>Clinical Cancer Research</i> , 2013 , 19, 500-7	12.9	94
303	Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. <i>Oncologist</i> , 2013 , 18, 353-61	5.7	57
302	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 640-7	10.3	137
301	Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. <i>Breast Journal</i> , 2013 , 19, 149-55	1.2	15
300	Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 286-91	4.6	26
299	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. <i>British Journal of Cancer</i> , 2013 , 109, 2959-64	8.7	229
298	Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013 , 29, 1463-73	2.5	20
297	Guidelines: usefulness and limitations. <i>Breast Care</i> , 2013 , 8, 172-3	2.4	2
296	Follow-up after breast cancer diagnosis. <i>Breast Care</i> , 2013 , 8, 457-60	2.4	2
295	Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy		6
294	Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials 2013 ,		32
293	Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer The phase III NATAN study (GBG 36/ABCSG XX) 2013 ,		4
292	Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 506-506	2.2	6
291	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 553-553	2.2	0
290	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 561-561	2.2	4
289	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e11601-e11601	2.2	2

288	BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 152-152	2.2	2
287	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 155-155	2.2	2
286	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 557-557	2.2	
285	Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 573-573	2.2	
284	A cross-section questionnaire to evaluate patients'satisfaction with totally implanted access ports (Port-a-Cath; PAC) and analysis of PAC-related complications at a tertiary care center.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20693-e20693	2.2	
283	Clinical management and resolution of stomatitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 558-558	2.2	2
282	BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 148-148	2.2	
281	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 151-151	2.2	
280	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1508-16	3.1	329
279	Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). <i>Annals of Surgical Oncology</i> , 2012 , 19, 1808-17	3.1	41
278	Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?. <i>Current Oncology Reports</i> , 2012 , 14, 35-43	6.3	12
277	Dual inhibition of HER2 in breast cancer treatment. <i>Lancet, The</i> , 2012 , 379, 596-8	4.0	3
276	253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. <i>European Journal of Cancer</i> , 2012 , 48, S116	7.5	3
275	Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2012 , 102, 10-3	5.3	60
274	Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. <i>British Journal of Cancer</i> , 2012 , 106, 25-31	8.7	60
273	Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. <i>Cancer Treatment Reviews</i> , 2012 , 38, 407-15	14.4	133
272	Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012 , 48, 1932-8	7.5	39
271	Objectively measured breast symmetry has no influence on quality of life in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 130-6	3.6	14

270	Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. <i>Cancer Treatment Reviews</i> , 2012 , 38, 798-806	14.4	67
269	Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. <i>Cancer Treatment Reviews</i> , 2012 , 38, 815-24	14.4	15
268	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 520-9	59.2	2054
267	Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 519-26	3.1	16
266	Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 237-44	4.4	76
265	The sequential use of endocrine treatment for advanced breast cancer: where are we?. <i>Annals of Oncology</i> , 2012 , 23, 1378-86	10.3	51
264	Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1579-89	3.5	19
263	The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. <i>Annals of Oncology</i> , 2012 , 23, 2782-2790	10.3	29
262	Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. <i>Breast Care</i> , 2012 , 7, 61-66	2.4	7
261	Anticancer activity of bisphosphonates in breast cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 114-22	2.2	4
260	Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012 , 72, 293-298	2	2
259	Brain metastases free survival differs between breast cancer subtypes. <i>British Journal of Cancer</i> , 2012 , 106, 440-6	8.7	62
258	Effects of bone-targeted agents on cancer progression and mortality. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1059-67	9.7	157
257	Adjuvant bisphosphonates: a new standard of care?. <i>Current Opinion in Oncology</i> , 2012 , 24, 635-42	4.2	6
256	Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 722-8	2.2	73
255	Treatment of Bone Metastases in Patients with Advanced Breast Cancer. <i>Breast Care</i> , 2012 , 7, 92-98	2.4	10
254	8th European Breast Cancer Conference (EBCC-8), Vienna, March 21-24, 2012. <i>Breast Care</i> , 2012 , 7, 170-176	17.6	1
253	Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study 2012 ,		3

252	Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients 2012 ,		10
251	Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10501-10501	2.2	3
250	Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 512-512	2.2	3
249	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 542-542	2.2	1
248	Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 551-551	2.2	1
247	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 559-559	2.2	9
246	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 102-102	2.2	2
245	Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 104-104	2.2	3
244	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 125-125	2.2	4
243	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 99-99	2.2	2
242	Bisphosphonates: prevention of bone metastases in breast cancer. <i>Recent Results in Cancer Research</i> , 2012 , 192, 65-91	1.5	22
241	BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 539-539	2.2	
240	Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 514-514	2.2	
239	BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 540-540 ^{2.2}		
238	Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. <i>Neoplasia</i> , 2011 , 13, 980-90	6.4	12
237	Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. <i>Neoplasia</i> , 2011 , 13, 419-27	6.4	13
236	Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial. <i>European Journal of Cancer</i> , 2011 , 47, 6-7	7.5	21
235	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. <i>Lancet Oncology</i> , 2011 , 12, 631-41 ^{21.7}		374

234	Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts. <i>Breast Disease</i> , 2011 , 33, 71-81	1.6	4
233	Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts. <i>Disease Markers</i> , 2011 , 31, 55-65	3.2	33
232	Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14. <i>Breast Journal</i> , 2011 , 17, 230-8	1.2	5
231	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. <i>Surgery</i> , 2011 , 149, 311-20	3.6	83
230	Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 121-8	4.4	26
229	Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT ₁ N ₀ M ₀ , low rectal cancer: a phase II study. <i>Strahlentherapie Und Onkologie</i> , 2011 , 187, 100-7	4.3	22
228	NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. <i>World Journal of Surgery</i> , 2011 , 35, 1580-9	3.3	45
227	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. <i>Clinical Cancer Research</i> , 2011 , 17, 6012-20 ^{12.9}		468
226	Dosing of zoledronic acid throughout the treatment continuum in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 175-88	7	8
225	Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2653-9 ²		161
224	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. <i>Annals of Oncology</i> , 2011 , 22, 2546-2555	10.3	139
223	Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7828-34 ^{12.9}		12
222	Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data. <i>Clinical Investigation</i> , 2011 , 1, 97-107		1
221	St. Gallen 2011: Summary of the Consensus Discussion. <i>Breast Care</i> , 2011 , 6, 136-141	2.4	156
220	Zoledronic acid in breast cancer: latest findings and interpretations. <i>Therapeutic Advances in Medical Oncology</i> , 2011 , 3, 293-301	5.4	22
219	P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer. 2011 ,		2
218	S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. 2011 ,		21
217	S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. 2011 ,		13

216	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2000-12	15.9	137
215	Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 520-520	2.2	7
214	Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. <i>Disease Markers</i> , 2011 , 31, 55-65	3.2	23
213	Quality of life in patients with pancreatic cancer during neoadjuvant chemotherapy using gemcitabine and bevacizumab: A pilot study.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 330-330	2.2	
212	Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. <i>British Journal of Cancer</i> , 2010 , 103, 1201-8	8.7	26
211	Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3548-51	2.2	20
210	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1825-36	3.5	3
209	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients. <i>Breast Care</i> , 2010 , 5, 298-304	2.4	2
208	Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. <i>Breast Care</i> , 2010 , 5, 158-162	2.4	11
207	Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. <i>Onkologie</i> , 2010 , 33, 360-8		8
206	Breast Cancer: Rank Ligand Inhibition. <i>Breast Care</i> , 2010 , 5, 320-325	2.4	3
205	Prevention of bone metastases and management of bone health in early breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, 216	8.3	15
204	Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 267-74	3	9
203	HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. <i>Annals of Oncology</i> , 2010 , 21, 955-60	10.3	42
202	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. <i>Journal of Clinical Oncology</i> , 2010 , 28, 509-18	2.2	615
201	Closing in on the unknown enemy. <i>Lancet Oncology</i> , <i>The</i> , 2010 , 11, 402-3	21.7	1
200	10 years of ATAC: one question answered, many others unresolved. <i>Lancet Oncology</i> , <i>The</i> , 2010 , 11, 1109-11	21.7	0
199	Potential anticancer properties of bisphosphonates. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 1, S53-65	5.5	57

198	The evolution of bone-targeted therapies: introduction. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 2, S1	5.5	1
197	The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74 Suppl 1, S2-6	7	8
196	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1809-19	15.4	44
195	Abstract PD01-03: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer 2010 ,		3
194	Abstract PD09-05: Impact of Body Mass Index (BMI) on the Efficacy of Endocrine Therapy in Postmenopausal Breast Cancer Patients [An Analysis of the ABCSG 6 and 6a Trial 2010 ,		2
193	Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 512-512	2.2	8
192	Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 530-530	2.2	6
191	Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 533-533	2.2	10
190	The evolving role of zoledronic acid in early breast cancer. <i>OncoTargets and Therapy</i> , 2009 , 2, 95-104	4.4	6
189	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 679-91	59.2	871
188	Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5888-94 ^{12.9}		26
187	Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 123-36	5.4	5
186	Third consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2009 , 20, 1771-85 ^{0.3}		139
185	Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio. <i>Breast Care</i> , 2009 , 4, 155-161	2.4	2
184	Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. <i>Current Cancer Drug Targets</i> , 2009 , 9, 824-33	2.8	42
183	Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. <i>Endocrine-Related Cancer</i> , 2009 , 16, 73-83	5.7	3
182	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. <i>BMC Cancer</i> , 2009 , 9, 367	4.8	19
181	Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?. <i>Clinical Breast Cancer</i> , 2009 , 9 Suppl 1, S18-27	3	11

180	0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy. <i>Breast, 2009, 18, S53</i>	3.6	
179	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment, 2009, 115, 373-80</i>	4.4	8
178	Bisphosphonates as adjuvant therapy for breast cancer. <i>Current Breast Cancer Reports, 2009, 1, 54-63</i>	0.8	4
177	To measure the unmeasurable. <i>World Journal of Surgery, 2009, 33, 52-3</i>	3.3	
176	Breast cancer chemoprevention - a vision not yet realized. <i>European Journal of Cancer Care, 2009, 18, 438-46</i>	2.4	9
175	Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer. <i>European Journal of Surgical Oncology, 2009, 35, 264-70</i>	3.6	64
174	4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer [First results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). <i>European Journal of Cancer, Supplement, 2009, 7, 3</i>	1.6	12
173	Bisphosphonates in the adjuvant treatment of early breast cancer. <i>Breast Cancer Research, 2009, 11,</i>	8.3	78
172	Fighting overtreatment in adjuvant breast cancer therapy. <i>Lancet, The, 2009, 374, 2029-2030</i>	4.0	32
171	Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy. <i>Journal of Immunotherapy, 2009, 32, 638-54</i>	5	11
170	New results from the use of bisphosphonates in cancer patients. <i>Current Opinion in Supportive and Palliative Care, 2009, 3, 213-8</i>	2.6	18
169	Adjuvant Chemotherapy of Breast Cancer. <i>Breast Care, 2009, 4, 339-341</i>	2.4	
168	Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. <i>Oncology Reports, 2009, 21, 1585-92</i>	3.5	37
167	Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC + Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer. <i>2009,</i>		4
166	Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. <i>2009,</i>		6
165	Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells. <i>Journal of Clinical Oncology, 2009, 27, e22035-e22035</i>	2.2	
164	Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). <i>Journal of Clinical Oncology, 2009, 27, 1090-1090</i>	2.2	1
163	Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma. <i>European Journal of Cancer, 2008, 44, 866-75</i>	7.5	12

162	The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 857-862	3.6	10
161	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. <i>Lancet Oncology, The</i> , 2008 , 9, 840-9	21.7	309
160	Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 1767-74	12.9	73
159	Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. <i>Annals of Oncology</i> , 2008 , 19, 1837-41	10.3	14
158	Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 2082-7	12.9	26
157	Adjuvant Endocrine Therapy in Premenopausal Patients. <i>Breast Care</i> , 2008 , 3, 311-316	2.4	1
156	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008 , 19, 420-32	10.3	366
155	Breast-conserving therapy for centrally located breast cancer. <i>Annals of Surgery</i> , 2008 , 247, 470-6	7.8	38
154	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 203-13	4.4	32
153	The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 309-16	4.4	20
152	Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 859-70	7.4	4
151	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 903-10	3.5	38
150	(Neo-)adjuvant chemotherapy in breast cancer ¶Trials, errors and new rationales from the SABCS 2007. <i>Memo - Magazine of European Medical Oncology</i> , 2008 , 1, 23-26	0.3	
149	Cystic neoplasms of the pancreas: conservative or operative treatment?. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2008 , 40, 220-226	0.9	0
148	Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12.. <i>Journal of Clinical Oncology</i> , 2008 , 26, LBA4-LBA4	2.2	42
147	Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3859-65	2.2	442
146	Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 334-40	4	171
145	In Reply to Dr. Dizdar et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1651	4	

144	The use of a breast symmetry index for objective evaluation of breast cosmesis. <i>Breast</i> , 2007 , 16, 429-353.6	74
143	Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 45-52	4.4 18
142	Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. <i>Breast Cancer Research and Treatment</i> , 2007 , 104, 109-14	4.4 37
141	Breast reconstruction - a view from surgical oncology. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007 , 39, 295-298	0.9
140	Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breast defects. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007 , 39, 330-339	0.9 11
139	Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1845-53	9.7 232
138	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. <i>British Journal of Cancer</i> , 2007 , 97, 1021-7	8.7 73
137	Managing aromatase inhibitor-associated bone loss in breast cancer. <i>Women's Health</i> , 2007 , 3, 441-8	3 2
136	Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2012-8	2.2 77
135	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 215-25.3	25.3 83
134	Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 820-8	2.2 264
133	Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. <i>Clinical Cancer Research</i> , 2007 , 13, 4435-9	12.9 19
132	An oncoplastic procedure for central and medio-cranial breast cancer. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 1158-63	3.6 36
131	Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3853-8	2.2 123
130	Overexpression of the human homologue for <i>Caenorhabditis elegans</i> cul-4 gene is associated with poor outcome in node-negative breast cancer. <i>Anticancer Research</i> , 2007 , 27, 949-52	2.3 48
129	VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. <i>Surgery</i> , 2006 , 139, 839-46	3.6 121
128	Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4571-7	5.6 23
127	Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. <i>Radiology</i> , 2006 , 241, 441-8	20.5 52

126	Management of bone loss induced by aromatase inhibitors. <i>Cancer Investigation</i> , 2006 , 24, 328-30	2.1	12
125	Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology</i> , 2006 , 7, 991-6	21.7	198
124	Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells. <i>Clinica Chimica Acta</i> , 2006 , 364, 139-47	6.2	8
123	A Case of Phyllodes Tumor with Focal Transition into Low-Grade Lymphangiosarcoma. <i>Breast Care</i> , 2006 , 1, 391-394	2.4	1
122	The Endocrine Origin and Different Characters of Breast Cancers [Recent Research on Hormone Receptors and Endocrine Treatment*. <i>Breast Care</i> , 2006 , 1, 124-128	2.4	
121	Breast Cancer Chemoprevention [hot yet There. <i>Breast Care</i> , 2006 , 1, 295-296	2.4	
120	Breast conservation: evolution of surgical strategies. <i>Breast Journal</i> , 2006 , 12, S165-73	1.2	28
119	Aetiology and surgical management of toxic megacolon. <i>Colorectal Disease</i> , 2006 , 8, 195-201	2.1	44
118	Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 9-15	4.4	38
117	Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 135-41	4.4	87
116	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet</i> , 2005 , 366, 455-62	40	734
115	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet</i> , 2005 , 366, 2087-106	40	3823
114	Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. <i>European Journal of Cancer</i> , 2005 , 41, 2655-61	7.5	30
113	Preoperative chemotherapy with epirubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 441-5	2.4	12
112	A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. <i>British Journal of Cancer</i> , 2005 , 92, 1655-62	8.7	24
111	P81 Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. <i>Breast</i> , 2005 , 14, S38	3.6	18
110	Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?. <i>American Journal of Transplantation</i> , 2005 , 5, 788-94	8.7	48
109	Preoperative second-line chemotherapy induces objective responses in primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2005 , 117, 48-52	2.3	4

108	Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). <i>Journal of Clinical Oncology</i> , 2005 , 23, 527-527	2.2	47
107	Retroviral targeting of proliferating endothelial cells. <i>Acta Biochimica Polonica</i> , 2005 , 52, 731-5	2	2
106	Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. <i>Anticancer Research</i> , 2005 , 25, 4225-30	2.3	3
105	Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo 2004 , 24, 609		10
104	Dendritic cell vaccination in medullary thyroid carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 2944-53	12.9	52
103	The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2004 , 36, 41-45	0.9	3
102	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2004 , 116, 26-31	2.3	33
101	High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 243-7	3.6	36
100	Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. <i>Annals of Surgery</i> , 2004 , 240, 306-12	7.8	193
99	Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. <i>Oncology Reports</i> , 2004 , 12, 495	3.5	4
98	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004 , 22, 553-553	2.2	13
97	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004 , 22, 553-553	2.2	3
96	Effect of neoadjuvant chemotherapy with gemcitabine and docetaxel on 3-year survival and resection rate in previously unresectable locally advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4234-4234	2.2	2
95	Gastrointestinal autonomic nerve tumors: a surgical point of view. <i>World Journal of Gastroenterology</i> , 2004 , 10, 2447-51	5.6	7
94	Dendritic cell-based vaccination in solid cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 135-42	2.2	112
93	Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. <i>Endocrine-Related Cancer</i> , 2003 , 10, 91-8	5.7	53
92	Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells 2003 , 22, 1397		4
91	. <i>Annals of Surgery</i> , 2003 , 237, 556-564	7.8	12

90	Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. <i>Annals of Surgery</i> , 2003 , 237, 556-64	7.8	20
89	Impact of pretreatment thrombocytosis on survival in primary breast cancer. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 1098-1106	7	107
88	Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. <i>Oncology Research and Treatment</i> , 2003 , 26, 115-9	2.8	1
87	Future Directions in the Treatment of Breast Cancer □ Cellular Interventions Using Dendritic Cells. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 119-123	4.4	
86	Future Directions in the Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 117-118	4.4	42
85	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 1-7	4.4	31
84	Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 82, 207-13	4.4	49
83	Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene. <i>Langenbecks Archives of Surgery</i> , 2003 , 388, 3-8	3.4	8
82	Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2003 , 35, 342-343	0.9	
81	Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. <i>Cancer</i> , 2003 , 98, 2291-301	6.4	14
80	Do we need HER-2/neu testing for all patients with primary breast carcinoma?. <i>Cancer</i> , 2003 , 98, 2547-53	3.4	72
79	Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. <i>International Journal of Cancer</i> , 2003 , 104, 677-82	7.5	125
78	Exact log-rank tests for unequal follow-up. <i>Biometrics</i> , 2003 , 59, 1151-7	1.8	43
77	Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. <i>Journal of Clinical Oncology</i> , 2003 , 21, 984-90	2.2	46
76	In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. <i>International Journal of Oncology</i> , 2003 , 22, 651-6	1	4
75	Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 155-9	3.5	15
74	Intraductal papillary-mucinous adenoma associated with unusual focal fibromatosis: a "postoperative" stromal nodule. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 441, 308-11	5.1	12
73	Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. <i>American Journal of Roentgenology</i> , 2002 , 179, 1503-7	5.4	117

72	Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1098-104	5.6	26
71	Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4621-7	2.2	238
70	Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. <i>Anti-Cancer Drugs</i> , 2002 , 13, 67-74	2.4	19
69	Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. <i>Clinical Breast Cancer</i> , 2002 , 3, 65-72	3	78
68	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 1831-7	12.9	275
67	Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 1-8	4.4	46
66	Prognostic relevance of three histological grading methods in breast cancer 2001 , 19, 1271		
65	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001 , 85, 1850-2	8.7	30
64	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. <i>Anti-Cancer Drugs</i> , 2001 , 12, 209-12	2.4	7
63	Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis. <i>Anticancer Research</i> , 2001 , 21, 295-300	2.3	12
62	Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. <i>Clinical Cancer Research</i> , 2001 , 7, 1669-75	12.9	105
61	Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. <i>Cancer Gene Therapy</i> , 2000 , 7, 66-73	5.4	133
60	Die axilläre Lymphknotendisektion in der Therapie des Mammakarzinoms. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2000 , 32, 119-123	0.9	
59	Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. <i>Cytokine</i> , 2000 , 12, 339-47	4	39
58	Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). <i>Cytokine</i> , 2000 , 12, 992-1000	4	39
57	The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. <i>Journal of Surgical Research</i> , 2000 , 91, 26-31	2.5	113
56	TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. <i>Clinical Cancer Research</i> , 2000 , 6, 50-6	12.9	175
55	Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. <i>Anticancer Research</i> , 2000 , 20, 4599-604	2.3	8

54	Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1701-9	2.2	26
53	Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. <i>Human Gene Therapy</i> , 1999 , 10, 649-57	4.8	79
52	Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. <i>European Journal of Cancer</i> , 1999 , 35, 398-405	7.5	29
51	Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSCG) trial 5. <i>European Journal of Cancer</i> , 1999 , 35, S83	7.5	15
50	Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature. <i>Surgery</i> , 1999 , 126, 890-899	3.6	27
49	Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?. <i>Journal of Immunotherapy</i> , 1999 , 22, 85-9	5	2
48	Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. <i>Annals of Surgery</i> , 1999 , 230, 352-60; discussion 360-1	7.8	30
47	Die Chirurgie des Mammacarcinoms. <i>Onkologie Heute</i> , 1999 , 27-37		
46	Experimentelle Therapie von Lebermetastasen. <i>Onkologie Heute</i> , 1999 , 167-174		
45	In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). <i>Cancer Research</i> , 1999 , 59, 205-12	10.1	32
44	It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998 , 50, 37-46	4.4	48
43	Tamoxifen for early breast cancer: an overview of the randomised trials. <i>Lancet, The</i> , 1998 , 351, 1451-1467	4.7	3357
42	Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. <i>European Journal of Cancer</i> , 1998 , 34, 66-70	7.5	9
41	P60 Adjuvant radiotherapy has no benefit after primary breast cancer treatment in selected postmenopausal patients. <i>European Journal of Cancer</i> , 1998 , 34, S31	7.5	2
40	Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group. <i>Journal of Hepatology</i> , 1998 , 28, 497-503	13.4	12
39	Evaluation of needle size for breast biopsy: comparison of 14-, 16-, and 18-gauge biopsy needles. <i>American Journal of Roentgenology</i> , 1998 , 171, 59-63	5.4	54
38	Outcomes of surgical, percutaneous endoscopic, and percutaneous radiologic gastrostomies. <i>Archives of Surgery</i> , 1998 , 133, 1076-83		122
37	Haemophilus parainfluenzae liver abscess after successful liver transplantation. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 818-9	9.7	15

36	Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. <i>Radiology</i> , 1997 , 202, 421-9	20.5	56
35	p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. <i>European Journal of Cancer</i> , 1997 , 33, 39-44	7.5	69
34	Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem Mammakarzinom (II). <i>Acta Chirurgica Austriaca</i> , 1997 , 29, 62-67		4
33	The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 317-324	4.9	
32	Neoadjuvant Chemotherapy Enables Breast-Conserving Surgery in Patients with Very Large Breast Cancers: Preliminary Results. <i>Oncology Research and Treatment</i> , 1996 , 19, 242-246	2.8	4
31	Tumor recurrence after oLTX. <i>Transplant International</i> , 1996 , 9, S151-S154	3	5
30	Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996 , 111, 827-31; discussion 832	1.5	18
29	The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation. <i>Transplantation</i> , 1996 , 61, 554-60	1.8	37
28	Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?. <i>Breast Cancer Research and Treatment</i> , 1995 , 34, 213-9	4.4	10
27	Kann man einer hochselektierten Patientinnengruppe nach brusterhaltender Therapie wegen Mammakarzinoms die postoperative Nachbestrahlung ersparen?. <i>Acta Chirurgica Austriaca</i> , 1995 , 27, 269-273		4
26	Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. <i>Thrombosis Research</i> , 1995 , 80, 225-33	8.2	2
25	Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer. <i>British Journal of Cancer</i> , 1995 , 72, 51-5	8.7	39
24	Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. <i>Breast Cancer Research and Treatment</i> , 1994 , 32, 165-75	4.4	48
23	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994 , 120, 314-8	4.9	3
22	Reasons for 50% reduction in the number of organ donors within 2 years--opinion poll amongst all ICUs of a transplant centre. <i>Transplant International</i> , 1994 , 7 Suppl 1, S668-71	3	1
21	The Potential Impact of Tamoxifen in Breast Cancer Prevention. <i>Oncology Research and Treatment</i> , 1993 , 16, 297-303	2.8	1
20	Circulating ICAM-1: novel parameter of renal graft rejection. <i>Transplantation Proceedings</i> , 1993 , 25, 919-20		21
19	Impact of donor cause of death on renal graft function--a multivariate analysis of 1545 kidney transplants. <i>Transplantation Proceedings</i> , 1993 , 25, 3102-3	1.1	4

18	What do intensive care unit personnel think about organ donation? Opinion poll amongst transplant centers. <i>Transplantation Proceedings</i> , 1993 , 25, 3122-3	1.1	4
17	Impact of vesicoureteral reflux on graft survival in renal transplantation. <i>Transplantation Proceedings</i> , 1993 , 25, 1058-9	1.1	16
16	DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. <i>European Journal of Cancer</i> , 1992 , 28, 711-6	7.5	21
15	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. <i>Transplant International</i> , 1992 , 5, S116-S120	3	9
14	Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 118, 629-34	4.9	15
13	Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. <i>International Journal of Cancer</i> , 1992 , 52, 707-12	7.5	33
12	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. <i>Transplant International</i> , 1992 , 5 Suppl 1, S116-20	3	3
11	Cadaveric kidney donation beyond the age of 60 years--a comparative analysis of 1180 grafts from different donor age groups. <i>Transplant International</i> , 1992 , 5 Suppl 1, S47-50	3	
10	Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1991 , 23, 2269-71	1.1	11
9	Soluble interleukin-2 receptor in liver transplant recipients. <i>Transplantation Proceedings</i> , 1991 , 23, 1417-8.1	8.1	2
8	Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver?. <i>Transplantation Proceedings</i> , 1991 , 23, 1567-8	1.1	53
7	Pancreatic transplantation with venous portal drainage. <i>Lancet, The</i> , 1989 , 2, 988	40	6
6	OKT3 immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1989 , 21, 2253-4	1.1	7
5	Chirurgische Probleme der Lebertransplantation. <i>Intensivmedizinisches Seminar</i> , 1989 , 117-123		
4	Indikationsstellung und Technik der Brusterhaltenden Operation	61-79	
3	Operative Taktik und Technik nach Präoperativer Chemotherapie	125-136	
2	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma		1
1	Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG). <i>Breast Care</i> , 1-9	2.4	

